Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6543458 | 0.86 | TSHR (0.35) | TSHRSMN1; SMN2 | |
| SCHEMBL21807520 | 0.80 | TSHR (0.35) | TSHRSMN1; SMN2 | |
| SCHEMBL276562 | 0.77 | TSHR (0.39) | TSHRSMN1; SMN2METAP1 | |
| SCHEMBL16681639 | 0.76 | TSHR (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL22575823 | 0.75 | TSHR (0.48) | TSHRSMN1; SMN2 | |
| SCHEMBL20530446 | 0.75 | LMNA (0.43) | TSHRSMN1; SMN2LMNA | |
| SCHEMBL730338 | 0.75 | LMNA (0.43) | TSHRSMN1; SMN2LMNA | |
| SCHEMBL21078330 | 0.74 | LMNA (0.31) | LMNA | |
| SCHEMBL27924161 | 0.73 | LMNA (0.41) | TSHRSMN1; SMN2LMNA | |
| Water SCHEMBL6553209 | 0.73 | LMNA (0.41) | TSHRSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402965-A1 | STEROL ANALOGS AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2022-12-22 | — | — | US | disclosed |
| EP-3852764-A1 | STEROL ANALOGS AND USES THEREOF | ModernaTX, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020061332-A1 | STEROL ANALOGS AND USES THEREOF | MODERNATX, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402965-A1 | STEROL ANALOGS AND USES THEREOF | NPC1L1, NPC1, SREBF2 | TSHR 2985/4885SMN1; SMN2 1624/4885METAP1 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.